Copy to clipboard 
CaP Biomaterials announced the resounding success of its defense of European Patent EP2632504, “Composites of hydroxyapatite and calcium carbonate and related methods or preparation and use,” by Omya International at the Board of Appeal at the European Patent Office. The protected inventions are useful in medical devices, such as Bone Void Fillers.
In 2021, The European Patent Office had fully rejected Omya’s initial Opposition, rejecting challenges by Omya to the validity of CaP’s European patent. Omya then filed for Appeal in 2022. After extensive discussions and review of all evidence presented to the experts of the Boards of Appeals of the EPO, the Board fully rejected the appeal of Omya on August 6, 2024. This decision has since been registered and published on the European Patent Register.
“As a high quality, niche player in this field, CaP Biomaterials is a committed and dedicated expert when it comes to calcium phosphates and related materials for medical devices. We continue to invest in our manufacturing capabilities, know-how and unique materials, including our composites of hydroxyapatite and calcium carbonate in order to create value for our customers. The decision of the Board of Appeal affirms the quality of CaP’s IP, the inventiveness and novelty of the material and processes. Our patent portfolio includes patents on calcium phosphates, bioglass and calcium carbonate materials, each one offering unique advantages to device developers and manufacturers and enable CaP to be a true value-added partner,” according to CaP’s site manager Onno Visser. “Larry Shimp and his team continue to develop novel processes and materials. It has been particularly rewarding to successfully defend this patent, being challenged by one of the world’s largest calcium carbonate manufacturers.”
CaP Biomaterials is a US-based contract manufacturer of calcium phosphates for medical devices, and its materials have been included in a significant number of 510(k)-cleared devices in recent years. CaP holds a portfolio of patents in both the US and Europe, offering a broad offering of materials to its customers to consider for their bone void fillers, additive manufacturing feedstock, polymer/ceramic composites or coating powders.
Source: CaP Biomaterials, LLC
